Predictors of response to second-line endocrine therapy for breast cancer

Breast Cancer Research and Treatment

Volumn 45, Issue 3, 1997, Pages 219-224

  Cheung, K L ^a   Willsher, P C ^a   Pinder, S E ^a   Ellis, I O ^a   Elston, C W ^a   Nicholson, R I ^b   Blamey, R W ^a   Robertson, J F R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b Tenovus Institute   (United Kingdom)

Author keywords

Breast cancer; Response; Second line endocrine therapy

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ESTROGEN RECEPTOR; GOSERELIN; HORMONE; MEGESTROL ACETATE; ONAPRISTONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; GONANES; GOSERELIN; HUMANS; MEGESTROL ACETATE; MIDDLE AGED; NITRILES; OVARIECTOMY; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; TAMOXIFEN; TRIAZOLES;

EID: 0030695954     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005828731462     Document Type: Article

References (18)

1. Nicholson RI, Bouzubar N, Walker KJ, McClelland R, Dixon AR, Robertson JFR, Ellis IO, Blamey RW: Hormone sensitivity in breast cancer: Influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer 27: 908-913, 1991
2. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JFR, Ellis IO, Blamey RW: Relationship between EGF-R, cerbB2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A: 1018-1023, 1993
3. Nicholson RI, McClelland RA, Gee JMW, Manning DL, Cannon P, Robertson JFR, Ellis IO, Blamey RW: Transforming growth factor-α and endocrine sensitivity in breast cancer. Cancer Res 54: 1684-1689, 1994
4. Gee JMW, Ellis IO, Robertson JFR, Willsher P, McClelland RA, Hewitt KN, Blamey RW, Nicholson RI: Immunocytochemical localization of Fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 64: 269-273, 1995
5. Nicholson RI, McClelland RA, Gee JMW, Manning DL, Cannon P, Robertson JFR, Ellis IO, Blamey RW: Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy. Breast Cancer Res Treat 29: 117-125, 1994
6. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JFR: Expression of ras p21 and c-erbB2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259-1266, 1995
7. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289-1293, 1977
8. Elston CW, Ellis IO: Prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow up. Histopath 19: 403-410, 1991
9. Nicholson RI, Campbell FC, Blamey RW, Elston CW, George D, Griffiths K: Steroid receptors in early breast cancer: value in prognosis. J Ster Biochem 15: 193, 1981
10. Robertson JFR, Bates K, Pearson D, Blamey RW, Nicholson RI: Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer 65: 727-730, 1992
11. Goulding H, Pinder SE, Cannon P, Pearson D, Nicholson RI, Snead D, Bell J, Elston CW, Robertson JFR, Blamey RW, Ellis IO: A new immunohistochemical antibody for the assessment of oestrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 26: 291-294, 1995
12. Nicholson RI, Colin P, Francis AB et al.: Evaluation of an enzyme immunoassay for oestrogen receptors in human breast cancer. Cancer Res (Suppl) 46: 4229s-4230s, 1986
13. Walker KJ, Bouzabar N, Robertson JFR et al.: Immunocytochemical localisation of estrogen receptor in human breast tissue. Cancer Res 48: 6517-6522, 1988
14. British Breast Group: Assessment of response to treatment in advanced breast cancer. Lancet 2: 38-39, 1974
15. Robertson JFR, Williams MR, Todd J, Nicholson RI, Morgan DAL, Blamey RW: Factors predicting the response of patients with advanced breast cancer to endocrine (megace) therapy. Eur J Cancer Clin Oncol 25: 469-475, 1989
16. Howell A, Mackintosh J, Jones M, Redford J, Wagstaff J, Sellwood RA: The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 24:1567-1572, 1988
17. Robertson JFR, Willsher PC, Cheung KL, Blamey RW: The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Proc ASCO 15: 101, 1996
18. Williams MR, Todd JH, Ellis IO, Dowle CS, Haybittle JL, Elston CW, Nicholson RI, Griffiths K, Blamey RW: Oestrogen receptor in primary and advanced breast cancer: An 8 year review of 704 cases. Br J Cancer 5: 67-73, 1987